NASDAQ:ACON Aclarion - ACON Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aclarion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.82 +0.01 (+1.23%) (As of 03/23/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.75▼$0.8350-Day Range$0.55▼$0.8352-Week Range$0.38▼$4.05Volume17,161 shsAverage Volume37,478 shsMarket Capitalization$6.48 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileAnalyst RatingsChartCompetitorsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Aclarion MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside264.0% Upside$3.00 Price TargetShort InterestHealthy1.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$12,043 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.98 out of 5 stars 3.5 Analyst's Opinion Consensus RatingAclarion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Aclarion has a forecasted upside of 264.0% from its current price of $0.82.Amount of Analyst CoverageAclarion has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.22% of the float of Aclarion has been sold short.Short Interest Ratio / Days to CoverAclarion has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aclarion has recently decreased by 0.17%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAclarion does not currently pay a dividend.Dividend GrowthAclarion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACON. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Aclarion this week, compared to 0 articles on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aclarion insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,043.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders22.10% of the stock of Aclarion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.02% of the stock of Aclarion is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioAclarion has a P/B Ratio of 3.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aclarion (NASDAQ:ACON) StockAclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.Read More Receive ACON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aclarion and its competitors with MarketBeat's FREE daily newsletter. Email Address ACON Stock News HeadlinesMarch 17, 2023 | americanbankingnews.comAnalyzing Aclarion (NASDAQ:ACON) & Progenity (NASDAQ:PROG)March 7, 2023 | finance.yahoo.comAclarion Announces Alpesh Patel MD MBA as a Key Opinion Leader Physician AdvisorMarch 23, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.February 16, 2023 | finance.yahoo.comAclarion to Present at Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference on February 21st - 24th, 2023February 15, 2023 | finance.yahoo.comAclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine SymposiumFebruary 5, 2023 | finance.yahoo.comInsiders who bought stock earlier this year lose -US$213k as Aclarion, Inc. (NASDAQ:ACON) drops to US$4.7mJanuary 31, 2023 | finance.yahoo.comGregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon AdvisorJanuary 17, 2023 | finanznachrichten.deThe Investor Summit: Aclarion to Present at the Jan 26th Virtual Investor Summit Microcap EventMarch 23, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.January 17, 2023 | finance.yahoo.comAclarion to Present at the Jan 26th Virtual Investor Summit Microcap EventJanuary 17, 2023 | finance.yahoo.comAclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon AdvisorDecember 22, 2022 | finance.yahoo.comDr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon AdvisorDecember 21, 2022 | finance.yahoo.comAclarion’s Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MDDecember 19, 2022 | finance.yahoo.comAclarion Adds to Growing Key Opinion Leader Program with Juan Uribe M.D. as a Surgeon AdvisorDecember 1, 2022 | finance.yahoo.comAclarion Adds to Strong Patent Portfolio with Notice of Allowance for New U.S. Patent Application Addressing Key Pain Indicator BiomarkerNovember 30, 2022 | reuters.comACON.OQ - Aclarion Inc | Stock Price & Latest News | ReutersNovember 16, 2022 | finance.yahoo.comAclarion Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsOctober 25, 2022 | finance.yahoo.comAclarion, Inc. Releases Updated Investor Presentation In Connection with Appearance at LD Micro Main Event XVOctober 24, 2022 | finance.yahoo.comDr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon AdvisorOctober 12, 2022 | finance.yahoo.comAclarion To Present at The LD Micro Main Event XVOctober 10, 2022 | finanznachrichten.deAclarion Inc.: Aclarion Announces Participation at the NASS 37th Annual MeetingOctober 10, 2022 | finance.yahoo.comAclarion Announces Participation at the NASS 37th Annual MeetingOctober 5, 2022 | finanznachrichten.deAclarion Inc.: John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon AdvisorOctober 3, 2022 | finance.yahoo.comJohn Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon AdvisorSeptember 20, 2022 | finanznachrichten.deAclarion Inc.: Nociscan Selected for Inclusion in Pivotal National Institutes of Health Study for Low Back PainSeptember 19, 2022 | finance.yahoo.comNociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back PainAugust 22, 2022 | msn.comPeering Into Aclarion's Recent Short InterestSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ACON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aclarion and its competitors with MarketBeat's FREE daily newsletter. Email Address ACON Company Calendar Today3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACON CUSIPN/A CIK1635077 Webwww.aclarion.com Phone833-275-2266FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$3.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+264.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,610,000.00 Net Margins-12,583.55% Pretax Margin-12,583.55% Return on EquityN/A Return on Assets-206.46% Debt Debt-to-Equity RatioN/A Current Ratio1.40 Quick Ratio1.40 Sales & Book Value Annual Sales$60,000.00 Price / Sales107.96 Cash FlowN/A Price / Cash FlowN/A Book Value$0.23 per share Price / Book3.58Miscellaneous Outstanding Shares7,860,000Free Float6,124,000Market Cap$6.48 million OptionableNot Optionable BetaN/A Key ExecutivesDr. Jeffrey John Thramann M.D. (Age 58)Exec. Chairman Comp: $300kMr. Brent Ness (Age 56)CEO, Pres & Director Comp: $339.6kMr. John Lorbiecki (Age 59)Chief Financial Officer Comp: $225kMr. Ryan Bond (Age 48)Chief Strategy Officer Comp: $202.6kKey CompetitorsAnPac Bio-Medical ScienceNASDAQ:ANPCBioceptNASDAQ:BIOCVyant BioNASDAQ:VYNTOpGenNASDAQ:OPGNCentogeneNASDAQ:CNTGView All CompetitorsInsidersJeffrey John ThramannBought 1 shares on 2/16/2023Total: $1,000.00 ($1,000.00/share)John Paul LorbieckiBought 22,404 shares on 12/29/2022Total: $10,081.80 ($0.45/share)Brent NessBought 2,289 shares on 12/28/2022Total: $961.38 ($0.42/share)View All Insider Transactions ACON Stock - Frequently Asked Questions Should I buy or sell Aclarion stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aclarion in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACON shares. View ACON analyst ratings or view top-rated stocks. What is Aclarion's stock price forecast for 2023? 1 brokers have issued 12-month price objectives for Aclarion's shares. Their ACON share price forecasts range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 264.0% from the stock's current price. View analysts price targets for ACON or view top-rated stocks among Wall Street analysts. How have ACON shares performed in 2023? Aclarion's stock was trading at $0.58 at the beginning of the year. Since then, ACON stock has increased by 42.1% and is now trading at $0.8241. View the best growth stocks for 2023 here. When did Aclarion IPO? (ACON) raised $12 million in an IPO on Friday, April 22nd 2022. The company issued 2,165,000 shares at a price of $4.50-$6.50 per share. What is Aclarion's stock symbol? Aclarion trades on the NASDAQ under the ticker symbol "ACON." How do I buy shares of Aclarion? Shares of ACON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aclarion's stock price today? One share of ACON stock can currently be purchased for approximately $0.82. How much money does Aclarion make? Aclarion (NASDAQ:ACON) has a market capitalization of $6.48 million and generates $60,000.00 in revenue each year. How can I contact Aclarion? Aclarion's mailing address is 951 MARINERS ISLAND BLVD STE 300, SAN MATEO CA, 94404. The official website for the company is www.aclarion.com. The company can be reached via phone at 833-275-2266. This page (NASDAQ:ACON) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.